In vitro antimicrobial activities of capuramycin analogues against non-tuberculous mycobacteria.
OBJECTIVE
To determine antibacterial activity of capuramycin analogues SQ997, SQ922, SQ641 and RKS2244 against several non-tuberculous mycobacteria (NTM).


METHODS
In vitro antibiotic activities, i.e. MIC, MBC, rate of killing and synergistic interaction with other antibiotics, were evaluated.


RESULTS
SQ641 was the most active compound against all the NTM species studied. The MIC of SQ641 was ≤0.06-4 mg/L for Mycobacterium avium complex (MAC; n = 20), 0.125-2 mg/L for M. avium paratuberculosis (MAP; n = 9), 0.125-2 mg/L for Mycobacterium kansasii (MKN;n = 2), 0.25-1 mg/L for Mycobacterium abscessus (MAB; n = 11), 4 mg/L for Mycobacterium smegmatis (MSMG; n = 1), and 1 and 8 mg/L for Mycobacterium ulcerans (MUL; n = 1), by microdilution and agar dilution methods, respectively. SQ641 was bactericidal against NTM, with an MBC/MIC ratio of 1 to 32, and killed all mycobacteria faster than positive control drugs for each strain. In chequerboard titrations, SQ641 was synergistic with ethambutol against both MAC and MSMG, and was synergistic with streptomycin and rifabutin against MAB.


CONCLUSIONS
In vitro, SQ641 was the most potent of the capuramycin analogues against all NTM tested, both laboratory and clinical strains.
Sequella, Inc., Rockville, MD 20850, USA.
Tia
T
Dubuisson
Elena
E
Bogatcheva
Manju Y
MY
Krishnan
Michael T
MT
Collins
Leo
L
Einck
Carol A
CA
Nacy
Venkata M
VM
Reddy
D000617:Aminoglycosides / Q000737:chemistry* / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000737:chemistry* / Q000494:pharmacology*; D015169:Colony Count, Microbial; D004357:Drug Synergism; D004977:Ethambutol / Q000494:pharmacology; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods / Q000706:statistics & numerical data; D009161:Mycobacterium / Q000145:classification* / Q000187:drug effects* / Q000302:isolation & purification; D009164:Mycobacterium Infections / Q000382:microbiology; D015269:Mycobacterium avium Complex / Q000187:drug effects; D016927:Mycobacterium avium subsp. paratuberculosis / Q000187:drug effects; D019909:Mycobacterium kansasii / Q000187:drug effects; D020102:Mycobacterium smegmatis / Q000187:drug effects; D019911:Mycobacterium ulcerans / Q000187:drug effects
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; C049983:capuramycin; D004977:Ethambutol